S&P 500   4,577.11
DOW   35,368.47
QQQ   370.55
S&P 500   4,577.11
DOW   35,368.47
QQQ   370.55
S&P 500   4,577.11
DOW   35,368.47
QQQ   370.55
S&P 500   4,577.11
DOW   35,368.47
QQQ   370.55

Corvus Pharmaceuticals Stock Forecast, Price & News

-0.23 (-10.22%)
(As of 01/18/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
434,009 shs
Average Volume
450,537 shs
Market Capitalization
$94.03 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive CRVS News and Ratings via Email

Sign-up to receive the latest news and ratings for Corvus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Corvus Pharmaceuticals logo

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of oncology therapies. The firm focuses on disabling cancer's ability to subvert immune attack by inhibiting adenosine in the tumor microenvironment and by blocking its production by tumors. Its product pipeline includes B Cell Activator, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson and Joseph J. Buggy on January 27, 2014 and is headquartered in Burlingame, CA.


2 Biotech Stocks That Surged More Than 100% in September
October 6, 2021 |  finance.yahoo.com
4 Buy-Ranked Stocks that Soared Over 20% in the Past Week
September 29, 2021 |  finance.yahoo.com
Why Corvus Pharmaceuticals Stock Is Down Today
September 22, 2021 |  finance.yahoo.com
Corvus Flat on Drug Trial News
September 22, 2021 |  baystreet.ca
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
Book Value
$2.54 per share


Net Income
$-5.99 million
Pretax Margin




Free Float
Market Cap
$94.03 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.47 out of 5 stars

Medical Sector

149th out of 1,414 stocks

Pharmaceutical Preparations Industry

62nd out of 682 stocks

Analyst Opinion: 3.4Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 1.3 5 -4 -3 -2 -1 -

Corvus Pharmaceuticals (NASDAQ:CRVS) Frequently Asked Questions

Is Corvus Pharmaceuticals a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corvus Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Corvus Pharmaceuticals stock.
View analyst ratings for Corvus Pharmaceuticals
or view top-rated stocks.

How has Corvus Pharmaceuticals' stock price been impacted by Coronavirus?

Corvus Pharmaceuticals' stock was trading at $2.71 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CRVS shares have decreased by 25.5% and is now trading at $2.02.
View which stocks have been most impacted by COVID-19

Are investors shorting Corvus Pharmaceuticals?

Corvus Pharmaceuticals saw a decline in short interest in December. As of December 31st, there was short interest totaling 223,500 shares, a decline of 31.2% from the December 15th total of 324,700 shares. Based on an average trading volume of 763,900 shares, the short-interest ratio is presently 0.3 days. Approximately 0.7% of the company's stock are short sold.
View Corvus Pharmaceuticals' Short Interest

When is Corvus Pharmaceuticals' next earnings date?

Corvus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, March 24th 2022.
View our earnings forecast for Corvus Pharmaceuticals

How were Corvus Pharmaceuticals' earnings last quarter?

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) released its quarterly earnings data on Sunday, October, 31st. The company reported ($0.24) earnings per share for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.24).
View Corvus Pharmaceuticals' earnings history

What price target have analysts set for CRVS?

4 Wall Street analysts have issued 12-month target prices for Corvus Pharmaceuticals' stock. Their forecasts range from $3.50 to $8.00. On average, they expect Corvus Pharmaceuticals' stock price to reach $6.38 in the next year. This suggests a possible upside of 215.6% from the stock's current price.
View analysts' price targets for Corvus Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Corvus Pharmaceuticals' key executives?

Corvus Pharmaceuticals' management team includes the following people:
  • Richard A. Miller, Chairman, President & Chief Executive Officer
  • Leiv Lea, Chief Financial Officer
  • Suresh Mahabhashyam, Vice President-Clinical Development
  • Joseph J. Buggy, Executive Vice President-Discovery Research
  • William B. Jones, Senior Vice President-Pharmaceutical Development

What is Richard A. Miller, MD's approval rating as Corvus Pharmaceuticals' CEO?

4 employees have rated Corvus Pharmaceuticals CEO Richard A. Miller, MD on Glassdoor.com. Richard A. Miller, MD has an approval rating of 100% among Corvus Pharmaceuticals' employees. This puts Richard A. Miller, MD in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Corvus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corvus Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Dynavax Technologies (DVAX), Vaxart (VXRT), Zosano Pharma (ZSAN), SCYNEXIS (SCYX), Miragen Therapeutics (MGEN), Aldeyra Therapeutics (ALDX) and Bionano Genomics (BNGO).

When did Corvus Pharmaceuticals IPO?

(CRVS) raised $75 million in an IPO on Wednesday, March 23rd 2016. The company issued 4,700,000 shares at $15.00-$17.00 per share. Credit Suisse and Cowen and Company acted as the underwriters for the IPO and Guggenheim Securities, Cantor Fitzgerald and BTIG were co-managers.

What is Corvus Pharmaceuticals' stock symbol?

Corvus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRVS."

Who are Corvus Pharmaceuticals' major shareholders?

Corvus Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Cutler Group LP (0.00%). Company insiders that own Corvus Pharmaceuticals stock include Ecor1 Capital, Llc, Holdings A/S Novo, Orbimed Advisors Llc and Richard A Md Miller.
View institutional ownership trends for Corvus Pharmaceuticals

Which major investors are selling Corvus Pharmaceuticals stock?

CRVS stock was sold by a variety of institutional investors in the last quarter, including Cutler Group LP. Company insiders that have sold Corvus Pharmaceuticals company stock in the last year include Ecor1 Capital, Llc, and Orbimed Advisors Llc.
View insider buying and selling activity for Corvus Pharmaceuticals
or view top insider-selling stocks.

How do I buy shares of Corvus Pharmaceuticals?

Shares of CRVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Corvus Pharmaceuticals' stock price today?

One share of CRVS stock can currently be purchased for approximately $2.02.

How much money does Corvus Pharmaceuticals make?

Corvus Pharmaceuticals has a market capitalization of $94.03 million. The company earns $-5.99 million in net income (profit) each year or $0.06 on an earnings per share basis.

How many employees does Corvus Pharmaceuticals have?

Corvus Pharmaceuticals employs 42 workers across the globe.

What is Corvus Pharmaceuticals' official website?

The official website for Corvus Pharmaceuticals is www.corvuspharma.com.

Where are Corvus Pharmaceuticals' headquarters?

Corvus Pharmaceuticals is headquartered at 863 Mitten Road Suite102, BURLINGAME CA, 94010.

How can I contact Corvus Pharmaceuticals?

Corvus Pharmaceuticals' mailing address is 863 Mitten Road Suite102, BURLINGAME CA, 94010. The company can be reached via phone at (650) 900-4520 or via email at [email protected].

This page was last updated on 1/19/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.